Viramune Print Ad Cited By FDA For Risk Minimization
This article was originally published in The Pink Sheet Daily
Executive Summary
Boxed text providing risk information for the HIV therapy uses print that is too small and omits necessary statements, FDA's ad division says. Boehringer Ingelheim must present FDA with a plan to discontinue using the ad by Oct. 6.